Search

Objectives: Growing evidence exists about post‐COVID condition/syndrome as sequelae of Sars‐CoV‐2 infection in healed patients, possibly involving the lungs, brain, kidney, cardiovascular and neuromuscular system, as well the persistency of taste dysfunction. Such symptoms develop during or after infection and continue for more than 12 weeks with pathogenesis related to virus persistency but variable by organs or systems. Materials and Methods: We recently observed six patients recovered from COVID‐19 and with negative RT‐PCR testing, showing oral mucosa lesions (mainly ulcers) overlapping those occurring in the acute phase, persisting up to 20 days and thus needing a biopsy with histological investigation and spike protein evaluation by immunohistochemistry. Results: We found epithelial ulceration, inflammatory infiltrate, vessels with increased diameter and flattened endothelium but no thrombi formation; also, we found a weak epithelial SARS‐CoV‐2 positivity limited to the basal/spinosum layers, progressively decreasing toward the periphery, and the intraepithelial lymphomonocytes, endothelium, and perivascular pericytes too. Conclusions: Our findings provide evidence that SARS‐CoV‐2 can persist, as for other organs/systems, also in the oral epithelium/mucosa after the acute phase and can be responsible for lesions, although by a pathogenetic mechanism that should be better defined but certainly referable as the oral mucosa counterpart of post‐COVID syndrome. [ABSTRACT FROM AUTHOR]

Objective: Oral lesions received increased attention as likely new signs or secondary manifestations of COVID‐19. Therefore, we clinically examined oral cavity of patients with COVID‐19 and investigated oral lesions and patient comorbidities as possible risk factors of COVID‐19 disease outcome. Methods: From January to March 2022, a prospective study was conducted by recruiting all COVID‐19 patients admitted to the Intensive Care Unit and Respiratory Intensive Care Unit of Maxi‐Emergencies Hospital in Bari, Italy. Results: From the enrolled 103 COVID‐19 patients, 46.6% were females and 53.4% were males. Findings show that risk of presenting with severe COVID‐19 disease was higher in patients who developed oral lesions related to COVID‐19 than those with no oral lesions (RR = 7.998, p =.002). Next, patients with concomitant autoimmune diseases were at higher risk of a negative COVID‐19 disease outcome than those without comorbidities (OR = 8.838, p =.026). Conclusions: COVID‐19‐related lesions of oral mucosa should not be ignored as they can be early and easily detectable signs of severe COVID‐19 disease condition, thus, serving as a prevention measure for any potential unfortunate event. Findings of this study, without implying causation, offer a direction for future investigations that aim to confirm the presence of specific oral lesions in COVID‐19 patients as signs of severe disease progression. [ABSTRACT FROM AUTHOR]

Background: Medication-related osteonecrosis of the jaws is the most frequent complication in patients treated or in therapy with antiresorptive/antiangiogenetic drugs. The list of medications possibly related to MRONJ onset is constantly growing; we aimed to report on a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (Osimertinib) as possibly responsible for bilateral maxillary necrosis onset in the herein-described case. Methods: In June 2023, an oncologic patient with two different maxillary bone exposures was referred to our attention. His medical history revealed a two-year Denosumab regimen along with Osimertinib, the latter not suspended before teeth extractions. The clinicians performed a sequestrum removal and bone debridement after three cycles of antibiotic therapy. Results: Histologic examinations confirmed the clinical diagnosis of MRONJ excluding a metastatic occurrence, while complete mucosal healing was achieved after 15 days. Conclusions: The patient suspended Denosumab for more than six months before teeth extraction for MRONJ prevention; hence, failure to discontinue Osimertinib led us to consider it a possible etiological factor. From a literature analysis, only one case has already been published reporting a possible Osimertinib-related occurrence of MRONJ in lung cancer patients. Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes. [ABSTRACT FROM AUTHOR]